BioAge (BIOA) shifted attention toward ophthalmic indications and a next-generation apelin program during a presentation at Citigroup's Biopharma Back to School Summit on September 9, 2026, signaling a broadening of its inflammatory-disease pipeline beyond cardiovascular endpoints.
The company's lead asset, BGE-102, an oral NLRP3 inhibitor, posted Phase I data published in April 2025 showing roughly 50% reductions in peripheral C-reactive protein (CRP) and approximately 50% cuts in interleukin-6 (IL-6) levels in both blood and cerebrospinal fluid. The oral formulation also demonstrated strong eye penetration — a property CEO Kristen Fortney cited as particularly relevant for intraocular applications, noting that "the blood-brain barrier and the blood-retina barrier are not dissimilar."
BioAge is advancing BGE-102 into a Phase II efficacy trial in diabetic macular edema (DME), the QUELL-DME study, which is enrolling about 180 patients across three arms: BGE-102 alone, VEGF therapy alone, and a combination arm. Top-line results are expected in the second half of 2026. Fortney highlighted that roughly 40% of the DME market opts for watchful waiting over injections, suggesting a receptive patient population. A clinically meaningful endpoint in the trial would be a one-line improvement in best-corrected visual acuity, equivalent to approximately five letters.
In the cardiovascular space, BGE-102 has been tested in the QUELL-CV study at once-daily doses of 30 mg, 60 mg, and 90 mg in obese, inflamed patients. Top-line data from that study is anticipated by the end of 2025. The research builds on precedent set by the CANTOS trial, which found that patients who normalized CRP experienced a 25% reduction in major adverse cardiovascular events (MACE) with an IL-1 beta antibody.
Beyond NLRP3, BioAge expects to file an investigational new drug application for its APJ agonist — or apelin — program by year-end 2025, opening a distinct mechanistic avenue. CFO Dov Goldstein said the company also aims to communicate at least one additional NLRP3 indication soon.
On the financial side, BioAge reported $381 million in cash at the end of Q2 2025, yielding a current ratio of 17.19 and a projected cash runway through 2029 — sufficient to fund operations and support one or two more NLRP3 indications. Wall Street price targets for BIOA ranged from $20 to $73. The stock traded at $9.17, down $0.22 or 2.34%, at the time of the summit.
Goldstein noted that a standard Phase II trial in a small indication runs roughly $20 million over about a year, while a large cardiovascular outcomes trial in the ASCVD space could require approximately $500 million spent over five to six years — underscoring the capital efficiency of BioAge's current pipeline positioning.
Broader inflammatory-market context was also referenced: Novo Nordisk's ARTEMIS trial, an IL-6 study in a CANTOS-like population, is expected to report top-line data in the first half of 2026, and additional data from Inflammasome Therapeutics is being monitored ahead of a summer 2025 readout.
